Although alirocumab and evolocumab have both been associated with improved outcomes in patients with dyslipidemia or established atherosclerotic cardiovascular disease, data on their respective performances are scarce. This study aimed at providing an indirect comparison of the efficacy and safety of alirocumab versus evolocumab.

Indirect Comparison of the Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Network Meta-Analysis

Sorrentino, Sabato;De Rosa, Salvatore;Indolfi, Ciro;
2020-01-01

Abstract

Although alirocumab and evolocumab have both been associated with improved outcomes in patients with dyslipidemia or established atherosclerotic cardiovascular disease, data on their respective performances are scarce. This study aimed at providing an indirect comparison of the efficacy and safety of alirocumab versus evolocumab.
2020
Alirocumab; Evolocumab; PCSK9 inhibitors; lipid lowering therapy
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/61795
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 39
  • ???jsp.display-item.citation.isi??? ND
social impact